title: Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells.
abstract: Androgen receptor (AR) signaling pathway remains the foremost target of novel therapeutics for castration-resistant prostate cancer (CRPC). However, the expression of constitutively active AR variants lacking the carboxy-terminal region in CRPC may lead to therapy inefficacy. These AR variants are supposed to support PCa cell growth in an androgen-depleted environment, but their mode of action still remains unresolved. Moreover, recent studies indicate that constitutively active AR variants are expressed in primary prostate tumors and may contribute to tumor progression. The aim of this study was to investigate the impact of constitutively active AR variants on the expression of tumor progression markers. N-cadherin expression was analyzed in LNCaP cells overexpressing the wild type AR or a constitutively active AR variant by qRT-PCR, Western blot and immunofluorescence. We showed here for the first time that N-cadherin expression was increased in the presence of constitutively active AR variants. These results were confirmed in C4-2B cells overexpressing these AR variants. Although N-cadherin expression is often associated with a downregulation of E-cadherin, this phenomenon was not observed in our model. Nevertheless, in addition to the increased expression of N-cadherin, an upregulation of other mesenchymal markers expression such as VIMENTIN, SNAIL and ZEB1 was observed in the presence of constitutively active variants. In conclusion, our findings highlight novel consequences of constitutively active AR variants on the regulation of mesenchymal markers in prostate cancer.
authors: INSERM U1113, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
authors: Félicie
authors: F
authors: Cottard
authors: Irène
authors: I
authors: Asmane
authors: Eva
authors: E
authors: Erdmann
authors: Jean-Pierre
authors: JP
authors: Bergerat
authors: Jean-Emmanuel
authors: JE
authors: Kurtz
authors: Jocelyn
authors: J
authors: Céraline
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D015820:Cadherins / Q000235:genetics; D045744:Cell Line, Tumor; D018450:Disease Progression; D014644:Genetic Variation; D018398:Homeodomain Proteins / Q000235:genetics; D006801:Humans; D008297:Male; D008648:Mesoderm / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000473:pathology*; D011944:Receptors, Androgen / Q000235:genetics*; D014157:Transcription Factors / Q000235:genetics; D015854:Up-Regulation; D014746:Vimentin / Q000235:genetics; D000071799:Zinc Finger E-box-Binding Homeobox 1
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; D018398:Homeodomain Proteins; D011944:Receptors, Androgen; D014157:Transcription Factors; D014746:Vimentin; C486307:ZEB1 protein, human; D000071799:Zinc Finger E-box-Binding Homeobox 1
references: Clin Cancer Res. 2011 Sep 15;17(18):5913-25
references: 21807635
references: Cancer Res. 2009 Jan 1;69(1):16-22
references: 19117982
references: Cancer Res. 2006 Apr 1;66(7):3365-9
references: 16585154
references: Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a003129
references: 20457567
references: PLoS One. 2008 Aug 06;3(8):e2888
references: 18682804
references: Hum Mutat. 2010 Jan;31(1):74-80
references: 19830810
references: Int J Dev Biol. 2004;48(5-6):463-76
references: 15349821
references: Prostate. 2006 Nov 1;66(15):1631-40
references: 16927303
references: Int J Cancer. 2007 Sep 15;121(6):1238-44
references: 17534890
references: Cancer Res. 2008 Jul 1;68(13):5469-77
references: 18593950
references: Int J Cancer. 2011 Jun 1;128(11):2545-61
references: 21365645
references: PLoS One. 2012;7(8):e42252
references: 22879924
references: Cell. 2008 May 16;133(4):704-15
references: 18485877
references: Mol Cell Biol. 2008 Mar;28(5):1528-40
references: 18172008
references: Oncogene. 2007 Jun 28;26(30):4453-63
references: 17297473
references: Prostate. 2010 Jun 15;70(9):982-92
references: 20166136
references: Endocr Relat Cancer. 2010 May 18;17(2):469-79
references: 20233707
references: J Cell Biol. 2000 Feb 21;148(4):779-90
references: 10684258
references: Cancer Res. 2009 Mar 15;69(6):2305-13
references: 19244107
references: Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34
references: 16025097
references: Biochim Biophys Acta. 2009 Dec;1796(2):75-90
references: 19306912
references: PLoS One. 2013;8(2):e57329
references: 23451207
references: Cancer Res. 2001 May 1;61(9):3819-25
references: 11325858
references: Mol Cell Biol. 2004 Sep;24(17):7559-66
references: 15314165
references: Asian J Androl. 2009 Jan;11(1):57-67
references: 19050684
references: J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):135-47
references: 20455012
references: Cancer Res. 2012 Jan 15;72(2):527-36
references: 22108827
references: Nat Med. 2010 Dec;16(12):1414-20
references: 21057494
references: PLoS One. 2011 Apr 28;6(4):e19059
references: 21552559
references: Exp Cell Res. 2011 Oct 15;317(17):2512-21
references: 21855541
references: Adv Exp Med Biol. 2008;617:529-34
references: 18497078
references: J Steroid Biochem Mol Biol. 2004 Nov;92(4):221-36
references: 15663986
references: Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65
references: 20823238
references: Prostate. 2005 Mar 1;62(4):364-73
references: 15389782
references: Cancer Res. 2013 Jan 15;73(2):483-9
references: 23117885
references: Nat Rev Cancer. 2009 Apr;9(4):265-73
references: 19262571
references: Cancer Res. 2000 Jul 1;60(13):3650-4
references: 10910081
references: J Clin Invest. 2009 Jun;119(6):1417-9
references: 19487817
references: J Biol Chem. 2002 Sep 6;277(36):32905-14
references: 12095980
references: Int J Cancer. 2004 Jan 1;108(1):152-7
references: 14618630
references: Hum Mutat. 2009 Feb;30(2):145-57
references: 18800375